Prognostic Role for CYFRA 21-1 in Patients With Advanced-stage NSCLC Treated With Bevacizumab Plus Chemotherapy
Language English Country Greece Media print
Document type Journal Article
PubMed
33813413
DOI
10.21873/anticanres.14974
PII: 41/4/2053
Knihovny.cz E-resources
- Keywords
- Bevacizumab, CEA, CYFRA, NSCLC, SCC, predictive, prognostic,
- MeSH
- Antigens, Neoplasm analysis blood physiology MeSH
- Bevacizumab administration & dosage adverse effects MeSH
- Biomarkers, Pharmacological analysis MeSH
- Carcinoembryonic Antigen analysis blood MeSH
- Keratin-19 analysis blood physiology MeSH
- Middle Aged MeSH
- Humans MeSH
- Biomarkers, Tumor analysis physiology MeSH
- Lung Neoplasms diagnosis drug therapy mortality pathology MeSH
- Carcinoma, Non-Small-Cell Lung diagnosis drug therapy mortality pathology MeSH
- Predictive Value of Tests MeSH
- Prognosis MeSH
- Disease Progression MeSH
- Antineoplastic Agents therapeutic use MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Serpins analysis blood MeSH
- Neoplasm Staging MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- antigen CYFRA21.1 MeSH Browser
- Antigens, Neoplasm MeSH
- Bevacizumab MeSH
- Biomarkers, Pharmacological MeSH
- Carcinoembryonic Antigen MeSH
- Keratin-19 MeSH
- KRT19 protein, human MeSH Browser
- Biomarkers, Tumor MeSH
- Antineoplastic Agents MeSH
- Serpins MeSH
- squamous cell carcinoma-related antigen MeSH Browser
AIM: To investigate potential associations between selected oncomarkers [carcinoembryonic antigen (CEA), C-terminus of cytokeratin 19 (CYFRA 21-1, CYFRA), and squamous cell carcinoma antigen (SCC)] and outcomes in patients with NSCLC treated with bevacizumab plus chemotherapy. PATIENTS AND METHODS: We retrospectively analysed 105 patients with NSCLC from the Czech TULUNG registry treated at University Hospital in Pilsen with bevacizumab plus chemotherapy. Response to therapy was tested by Fisher's exact test. Survival statistics were evaluated using the Kaplan-Meier method and Cox analysis. RESULTS: Only normal values of CYFRA (not CEA or SCC) were associated with significantly better overall and progression-free survival in univariate analysis. We also observed a trend for a better disease control rate in patients with normal levels of CYFRA. In a multivariate Cox model, only CYFRA was associated with significantly better overall but not progression-free survival. CONCLUSION: In our retrospective study, we point out the possibility of using CYFRA as a prognostic marker in patients with NSCLC treated with chemotherapy plus bevacizumab.
Department of Surgery Charles University Faculty of Medicine in Pilsen Pilsen Czech Republic
Institute of Biostatistics and Analyses Ltd Brno Czech Republic
References provided by Crossref.org
